PROKIDNEY Files 8-K for Reg FD Disclosure, Financials

Ticker: PROK · Form: 8-K · Filed: Jan 26, 2024 · CIK: 1850270

Prokidney Corp. 8-K Filing Summary
FieldDetail
CompanyProkidney Corp. (PROK)
Form Type8-K
Filed DateJan 26, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, financial-statements, corporate-governance

TL;DR

**PROKIDNEY just dropped an 8-K with Reg FD and financials, watch for potential news.**

AI Summary

PROKIDNEY CORP. filed an 8-K on January 25, 2024, primarily to disclose that it is making a Regulation FD Disclosure and to file Financial Statements and Exhibits. This filing indicates that the company is providing information that it deems important for investors, likely related to its ongoing operations or financial health. For investors, this matters because Regulation FD disclosures often precede or accompany significant news, and the inclusion of financial statements and exhibits suggests that more detailed information about the company's performance or strategic direction may be available, which could impact stock valuation.

Why It Matters

This filing signals that PROKIDNEY CORP. is releasing important information, potentially impacting its stock price as investors digest new financial or operational details.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of information, not indicating any immediate negative or positive event, thus posing low risk.

Analyst Insight

A smart investor would review the specific content of the Regulation FD Disclosure and the Financial Statements and Exhibits once they are publicly available to understand the implications for PROKIDNEY CORP.'s future performance and valuation.

Key Players & Entities

  • PROKIDNEY CORP. (company) — the registrant filing the 8-K
  • January 25, 2024 (date) — the date of the earliest event reported in the 8-K
  • Regulation FD Disclosure (other) — an item of information disclosed in the 8-K
  • Financial Statements and Exhibits (other) — an item of information disclosed in the 8-K

FAQ

What is the primary purpose of PROKIDNEY CORP.'s 8-K filing on January 25, 2024?

The primary purpose of PROKIDNEY CORP.'s 8-K filing on January 25, 2024, is to make a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated under 'ITEM INFORMATION'.

What is PROKIDNEY CORP.'s trading symbol and on which exchange are its securities registered?

PROKIDNEY CORP.'s trading symbol is PROK, and its Class A ordinary shares, $0.0001 par value per share, are registered on The Nasdaq Stock Market.

What is the business address of PROKIDNEY CORP. as stated in the filing?

The business address of PROKIDNEY CORP. is 2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, North Carolina, 27103.

What was PROKIDNEY CORP.'s former company name and when did the name change occur?

PROKIDNEY CORP.'s former company name was Social Capital Suvretta Holdings Corp. III, and the date of the name change was 20210310 (March 10, 2021).

What is the Commission File Number for PROKIDNEY CORP.?

The Commission File Number for PROKIDNEY CORP. is 001-40560.

Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-25 20:28:06

Key Financial Figures

  • $0.0001 — ch registered Class A ordinary shares, $0.0001 par value per share PROK The Nasdaq

Filing Documents

01

Item 7.01 Regulation FD Disclosure. ProKidney Corp. (the "Company") has updated its investor presentation (the "Presentation"), which its senior management intends to use from time to time when interacting with investors and analysts, among others. The Presentation is available on the Company's website at https://investors.prokidney.com/news-events/events-and-presentations. The Presentation is also attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this Item 7.01 and Exhibit 99.1 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Item 7.01 and Exhibit 99.1 is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Investor Presentation 104 Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROKIDNEY CORP. Date: January 25, 2024 By: /s/ Todd Girolamo Name: Todd Girolamo Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.